| Bioactivity | SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC50 values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone[1]. |
| Target | IC50: 2.8 nM (human); 1.4 nM (mouse). |
| Name | SSTR5 antagonist 3 |
| CAS | 2851454-42-5 |
| Formula | C31H36F2N2O5 |
| Molar Mass | 554.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Han F, et al. Discovery and exploration of novel somatostatin receptor subtype 5 (SSTR5) antagonists for the treatment of cholesterol gallstones. Eur J Med Chem. 2023 Dec 5;264:116017. |
SSTR5 antagonist 3
CAS: 2851454-42-5 F: C31H36F2N2O5 W: 554.62
SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.